Christopher Paul Simms

Christopher Paul Simms, listed as senior executive, appears in our data through filings on IVERIC bio, Inc. shares, published by SEC (Form 4). We count 8 filings; the first trade dates from 18 November 2021 and the latest from 11 July 2023.

The open-market side counts 1 purchase for €44k alongside 3 sales for €180k. The net balance comes to €136k on the selling side. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 option exercises. So far in 2023, the count stands at no purchases and 1 sale.

On 13 July 2023 came the latest disclosure, a transaction in IVERIC bio, Inc. The latest purchase dates back some time: it was published 1,812 days ago, on 22 November 2021. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.